CytRx Receives FDA Correspondence Regarding Phase IIb Arimoclomol Clinical Trial In ALS (Medical News Today)
CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, announced receipt of a written correspondence from the U.S.

Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia (The San Francisco Examiner)
CORONA, Calif. ( Map ) - CORONA, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading specialty pharmaceutical company, today announced that its New Drug Application (NDA) for silodosin, a novel alpha(1)- adrenoreceptor antagonist, has been accepted for filing by the U.S. Food and Drug Administration (FDA). Watson is seeking marketing approval of ...

Diamyd Medical: Diamyd Updates FDA IND Approval Status For Phase III Diamyd(R) Diabetes Study In The US (Medical News Today)
Diamyd Medical (NASDAQ:DMYDY) (STO:DIAMB) announced that it has received one FDA question relating to the US Phase III IND application for Diamyd in treatment of type 1 diabetes. The question has been answered with additional documentation and the FDA now has 30 days to respond.